Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed Maintenance in Urothelial Carcinoma (PREMIER)
NCT03193788Phase 3Unknown
- Sponsor
- Asan Medical Center
- Start
- Jan 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in urothelial carcinoma (UC) comparing Pemetrexed Maintenance with Observation (2 arms). Primary endpoint: Progression-Free Survival up to 24 months. Status: unknown.
02
Drugs
pemetrexed
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03193788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03193788.